je.st
news
Premarket Biotech Digest: Tracking Gilead HCV Sales, Shire-Baxalta Deal, AstraZeneca Deal
2015-12-17 17:08:44| Biotech - Topix.net
The current consensus forecast for fourth quarter HCV sales is $2.81 billion. In the third quarter, U.S. HCV sales had totaled $3.23 billion.
Tags: sales
deal
tracking
digest
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||